
Utilization of bacteriophages to combat *Campylobacter*

Mohamed S. Abd El Moneem ¹, Gamal El-Didamony ², Ibrahim M. Elshorbagy ³,
and Gamal Enan ^{4,*}

²Botany and Microbiology Department, Faculty of Science, Zagazig University

³Agriculture Research Center, Animal Health Research Institute, Cairo 12618, Egypt

⁴Botany and Microbiology Department, Faculty of Science, Zagazig University

ABSTRACT: *Campylobacter* infections are amongst the most frequently encountered foodborne bacterial infections around the world. Handling and consumption of raw or undercooked poultry products have been determined to be the main route of transmission. The ability to use phages to target these bacteria has been studied for more than a decade and although we have made progress towards deciphering how best to use phages to control *Campylobacter* associated with poultry production, there is still much work to be done. This review outlines methods to improve the isolation of these elusive phages, as well as methods to identify desirable characteristics needed for a successful outcome. It also highlights the body of research undertaken so far and what criteria to consider when doing in-vivo studies, especially because some in-vitro studies have not been found to translate into to phage efficacy in-vivo.

KEYWORDS: *Tamarindus indica*, *Staphylococcus aureus*, MDR

Date of Submission: 20-05-2023

Date of acceptance: 20-05-2023

1. Historical overview about *Campylobacter* spp.:

It is a well-known fact that poultry appeared to be a significant source of *Campylobacter* and chicken was found to be heavily intestinal carriers of *Campylobacter* when compared with other food animals (Humphrey *et al.*, 2007)

These variations in *Campylobacter* spp. prevalence might be due to differences in hygienic conditions, cross-contamination that may occur during de-feathering, eviscerating, and some other environmental factor such as the temperature of water in the scalding tank (Hagos *et al.*, 2021).

The prevalence of *Campylobacter* spp. in bovine meat was 11.90%. This was comparable to the finding reported from a previous study done by (Salihu *et al.*, 2009) (12.9%) in Nigeria, and (Taremi *et al.*, 2006) (10%) in Iran. However, it was higher than the findings reported by (Dadi L *et al.*, 2008) (6.2%) in Ethiopia (Nonga *et al.*, 2010); (5.6%) in Morogoro, Tanzania; and (Vanderlinde *et al.*, 1998) (0.8%) in Australia. Food of animal origin has been incriminated for being the main source of *Campylobacter* infection in humans (Oberhelman *et al.*, 2000).

Since raw meat from beef is widely consumed in the country; the occurrence of *Campylobacter* in meat increases the likelihood of the pathogen transmission to humans. The present finding was lower than studies conducted by (Salihu *et al.*, 2009) and (Thépault *et al.*, 2018) who reported a prevalence of 69.1% and 22%, respectively. One of the most likely hypotheses to explain the discrepancies is the differences in protocols used for the detection of thermophilic *Campylobacter*, and especially the absence of an enrichment step for the isolation of thermophilic *Campylobacter* in (Chatre *et al.*, 2010).

2 General description of Genus *Campylobacter*

Campylobacter spp. are Gram-negative, non-spore forming bacteria and are members of the family campylobacteraceae. The Genus *Campylobacter* comprises 17 species and 6 subspecies (Nachamkin, 2007; Silva *et al.*, 2011). The two species most commonly associated with human disease are *C. jejuni* and *C. coli*. *C. jejuni* accounts for more than 80% of campylobacter-related human illness, with *C. coli* accounting for up to 18.6% of human illness. *C. fetus* has also been associated with foodborne disease in humans (Gurtler *et al.*, 2005; FDA 2012).

The growth and survival of *Campylobacter* spp. depends on a variety of factors. *Campylobacter* spp. are sensitive to environmental conditions, such as temperature, availability of water and oxygen; and have limited capacity to survive environmental stresses. *Campylobacter* spp. grow in the 30-45°C. At 32°C, *C. jejuni* may double its number in approximately 6 h (Forsythe, 2000). *Campylobacter* spp. do not multiply at temperatures below 30°C, such that the number of *Campylobacter* spp. will not increase in foods held at room temperature (20-25°C) (Park, 2002).

Members of the genus *Campylobacter* are long spiral forms, curved, atypical Gram negative rods with size ranging from 0.2 to 0.8 µm wide and 0.5 to 5 µm long (Halablal *et al.*, 2008). *Campylobacter* cells transform from spiral form to coccoid morphology with less motility when aged or exposed to air for prolonged time periods (ISO, 2006). They are usually motile by means of a single polar unsheathed flagellum at one or both ends, but may also lack flagella. The uni-polar flagellum gives *Campylobacter* characteristic cork-screw motility (Song *et al.*, 2004).

3. *Campylobacter* infection in humans and poultry

Mäesaar *et al.* (2014) examined 606 poultry meat samples at retail level and 380 broiler chicken caecal samples at slaughterhouse level in Estonia for presence of *Campylobacter* spp. of the results showed that 20.8% of the poultry meat and 39.2% of the caecal samples were found positive for *Campylobacter* spp.

Torralbo *et al.* (2014) collected 2221 cloacal swabs and 747 environmental swabs from 291 broiler flocks from broiler farms in Andalusia (southern Spain). The prevalence of *Campylobacter* in individual birds was 38.1%, and the flock prevalence was 62.9%. Flocks were predominantly infected by *C. jejuni* and *C. coli* but were also infected.

Campylobacter species represent one of the most common causes of bacterial diarrheal illness worldwide. According to the United States Centers for Disease Control, there are about 1.3 million cases of *Campylobacter* infection each year in the United States alone. This leads to an economic cost between \$1.3 to 6.8 billion dollars annually in the United States (Kaakoush *et al.*, 2015). *Campylobacter* infection is associated with the consumption of raw milk, undercooked poultry, and contaminated water. Patients typically experience a self-limited diarrheal illness lasting 5 to 7 days. Immunocompromised and elderly patients are at the highest risk for morbidity, mortality and prolonged illness. Despite having treatment and eradication modalities in place in animal reservoirs, there has been a dramatic increase of cases in developed and underdeveloped regions of the world (Kaakoush. *et al.*, 2015).

4. Antimicrobial resistance

The un-controlled use of antibiotics in animal husbandry, for treatment and growth promotion has led to an increase in antibiotic resistant *Campylobacter* infections in humans (Iovine, 2013). Therefore, an understanding of the antibiotic resistance mechanisms in *C. jejuni* is needed to provide proper therapy both to the veterinary and human populations (Iovine, 2013).

In addition to intrinsic resistance mediated by efflux (Jeon *et al.*, 2011), antibiotic exclusion [via the major outer membrane porin (MOMP) (Page *et al.*, 1989), lipooligosaccharide and possibly capsule (Jeon *et al.*, 2011)] also contribute to intrinsic resistance (Figure 1).




Figure (1): Summary of major antibiotic resistance mechanisms in *Campylobacter* (Jeon *et al.*, 2011).

5. *Campylobacter* species virulence factors

Specific virulence mechanisms are not clearly demonstrated for *Campylobacter* species up till now, probably owing to the paucity of pathogenesis resemblance between *Campylobacter* and the other bacteria (Dasti *et al.*, 2010). Bacterial motility, adherence, invasion ability and toxins production have been described as virulence factors for *Campylobacter* spp. (Dasti, *et al.*, (2010), and Bhunia, 2018). (Figure 2) (Van Vliet, 2001) as following:




Figure (2): Diagram demonstrates the virulence attributes of *Campylobacter* species taken from a previous report (Van Vliet, 2001). IL-8: interleukin-8, NF-Kb: nuclear factor kappa-light-chain-enhancer of activated B cells

6. Characterization of *Campylobacter* phages

The use of phages to control pathogenic bacteria has been investigated since they were first discovered in the beginning of the 1900s. Over the last century we have slowly gained an in-depth understanding of phage biology including which phage properties are desirable when considering phage as biocontrol agents and which phage characteristics to potentially avoid. *Campylobacter* infections are amongst the most frequently encountered foodborne bacterial infections around the world. Handling and consumption of raw or undercooked poultry products have been determined to be the main route of transmission. The ability to use phages to target these bacteria has been studied for more than a decade and although we have made progress towards deciphering how best to use phages to control *Campylobacter* associated with poultry production, there is still much work to be done. This review outlines methods to improve the isolation of these elusive phages, as well as methods to identify desirable characteristics needed for a successful outcome. It also highlights the body of research undertaken so far and what criteria to consider when doing in-vivo studies, especially because some in-vitro studies have not been found to translate into phage efficacy in-vivo (Janež N. *et al.*, 2013)

The best sources to isolate phage are from environments where the host is highly prevalent. *Campylobacter* is ubiquitous in temperate environments but favors the intestine of all avians, where they colonize the gut as a commensal organism (Newell and Fearnley, 2003). By isolating the *Campylobacter* strains from the same location as their phage, there is a higher probability of having a host susceptible to the phages sought. Failing the possibility of isolating 'native' hosts, possessing a highly susceptible strain such as *C. jejuni* NCTC 12662, which is known to be sensitive to most *C. jejuni* and *C. coli* phage isolates, is an alternative solution (Connerton *et al.*, 2004; Loc Carrillo, 2005; Owens *et al.*, 2012).

Once isolated and purified, phages must undergo a variety of genotypic and phenotypic tests necessary to identify them as suitable candidates for use as biocontrol agents.

Determining the lytic activity of a phage is the most common characterization, because it can help determine if the phage should be tested further. Phages possessing broad lytic spectra are often highly desirable, although phages capable of lysing bacterial strains that are less susceptible to a wide variety of phages are also deemed beneficial. Lytic activity of a *Campylobacter* phage should be assessed with a panel of reference *Campylobacter* strains that include *C. jejuni* and *C. coli*, as well as wild-type isolates that reflect the environment under study (Hansen *et al.*, 2007). Other to determine how virulent the phage is towards the different strains.

6.1.1. Morphological characteristics

A slightly more technical but relatively fast characterization method commonly used is determining the structure of phages. Phages can be examined using transmission electron microscopy (TEM) (Ackermann, 2001) and more recently using atomic force microscopy (Kuznetsov *et al.*, 2011). It is advisable to have as high a titer of phage suspension as possible, with a minimum titer of c. 10⁸ PFU/mL necessary to locate phage on the surface of a carbon-coated copper grid. Phage suspensions may be concentrated using standard molecular protocols such as ultrafiltration membranes, polyethylene glycol (PEG) precipitation, or cesium chloride

equilibrium gradients (Sambrook and Russell, 2001). Simple preparations for examining Campylobacter phage under TEM are highlighted by (Atterbury *et al.* (2003a), and Owens *et al.* (2012)).

6.1.2. Protein profiling

Only two protein profiles of Campylobacter phage have been published to-date (Timms *et al.*, 2010; Hammerl *et al.*, 2011). (Timms *et al.* (2010) used precast gels. They loaded their purified phage suspension (c. 1010 PFU/mL) to gradient gels using the manufacturer's SDS sample and gel running buffers, and followed the manufacturers' instructions. The gels were run at 200 V for 35–50 min, and stained with colloidal coomassie blue. Protein bands were excised and digested with trypsin, before undergoing electrospray ionization followed by tandem mass spectrometry (MS/MS). Both research groups used the Mascot Daemon web server database to analyze their peptide sequences.

6.1.3. Genomic characterization

Pulsed-Field Gel Electrophoresis has been used extensively to determine the genome size of most Campylobacter phages characterized to-date (Sails *et al.*, 1998; Atterbury *et al.*, 2003a). It is recommended to use at least a 109 PFU/mL suspension of phage for genome size determination, and higher titers for restriction endonuclease analysis. Once embedded in an agarose block, the protein-based structures of the phage are degraded using proteinase K and a detergent (e.g., lauryl sarkosyl). Proteinase K is then inactivated by washing the agarose block at 55 °C and the washed block can be stored in TE buffer at 4 °C for no more than 3 months. For restriction digest analysis, a number of restriction enzymes have been used, although most have failed to produce a restriction profile (Sails *et al.*, 1998; Hwang *et al.*, 2009; Owens *et al.*, 2012).

Electrophoretic parameters used to analyze the PFGE profile are dependent on the speculated fragment sizes, and PFGE apparatus manufacturers such as Biorad provide helpful guidelines in their equipment manuals. As size standards the MidRange I PFG Marker by New England Biolabs or lambda concatemer have been successfully used. Analysis at the genomic level was first performed for the set of 16 Campylobacter typing phages (Sails *et al.*, 1998). The majority of Campylobacter phages possessing icosahedral heads and contractile tails isolated so far may be grouped according to their genome sizes (Sails *et al.*, 1998; Connerton *et al.*, 2011).

Preparation of genomic DNA for sequencing requires highly purified, high titer phage suspensions. A variety of protocols have been used to isolate Campylobacter phage DNA, as has the technology to generate DNA libraries, including use of the Roche's 454 Genome Sequencer FLX system (Timms *et al.*, 2010; Hammerl *et al.*, 2011; Carvalho *et al.*, 2012); proprietary technology by Fidelity Systems (Kropinski *et al.*, 2011); and shotgun sequencing (Timms *et al.*, 2010). The extraction methods used to obtain Campylobacter phage DNA plays an important part in the information obtained. Proteins, which have been found to be tightly bound to phage DNA, tend to be removed during the phenol extraction procedure along with a significant amount of (N80%) DNA. Separation of DNA from proteins has also proved problematic with the Qiagen genomic DNA purification kit columns (Kropinski *et al.*, 2011). To add, phage genome sequencing has proved difficult due to their refractory properties to restriction enzyme digestion and an inability to amplify DNA with regular Taq polymerase. It may be worth noting that due to the small number of phage genomes sequenced so far, and the limited bioinformatics data available to identify and annotate genes, sequencing a phage does not guarantee to determine if the phage carries 'unknown' genes coding for lysogeny, or ones that can promote a bacterium's virulence or

7. Interaction between Campylobacter phages and their hosts

Since phage genome sequencing is still in its infancy stage, it is important to study the phage-host interactions through both in-vitro and in-vivo studies in order to understand development of resistance. (Holst Sorensen *et al.* (2011) used the well-characterized Campylobacter jejuni NCTC11168 strain to select for a phage-resistant mutant, in order to determine the receptor site for Campylobacter phage F336. By using periodate or proteinase K, they were able to elucidate that phage binding was due to a carbohydrate moiety rather than an outer membrane protein on the surface of the phage-resistant mutant strain. With the aid of high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) analysis of intact bacterial cells, they found that the difference between the susceptible wild type and resistant strain was a modification of the capsular polysaccharide's (CPS) hyper variable O-methyl phosphoramidate structure. This structure has been found to be highly abundant in *C. jejuni* strains although it is unknown how a defect within this structure affects the virulence of the resistant-mutant strain (Holst Sorensen *et al.*, 2011). Scott *et al.* (2007a) used in-vivo studies to investigate how Campylobacter phage CP34 predation upon *C. jejuni* HPC5 populations in the avian gut, would affect the development of phage-resistant mutants. Three phenotypes were discovered from the strains isolated: resistance to phage, poor colonisers of the chicken intestine, and producers of a functional Mu-like phage, although these were not seen with *in-vitro* kinetics studies. These phenotypes resulted from intra-genomic inversions between Mu-like prophage sequences present in the parental strain. Interestingly, the reintroduction of these phenotypes to chickens in the absence of phage predation resulted in bacterial genomic rearrangements that lead the population to regain their competency at colonizing the chicken gut as well as revert back to being sensitive to phage (Scott *et al.*, 2007a). The intriguing differences between results obtain

from in-vitro and in-vivo kinetic studies of phage-host interactions can be highlighted by the work published by **Loc Carrillo et al. (2005)**. A particular *C. jejuni* strain (HPC5) was tested for its development of phage resistance to two different Campylobacter phages (CP8 and CP34) both in-vitro and in-vivo. In-vitro studies showed 8% and 11% of the colonies tested became resistant to successive CP8 and CP34 phage infections, respectively. In contrast, only 4% of colonies recovered from the CP34 phage treated in-vivo studies gained resistance. Furthermore, isolates from the in-vitro studies were not found to revert back to the sensitive phenotype after five consecutive subcultures. Kinetic differences between these two phages and the target bacteria were also found to have considerably different behaviors between their in-vitro and in-vivo environments, as highlighted below (**Loc Carrillo et al., 2005**).

7.1 Use of phages to control Campylobacter in live birds and food products

To-date, there have been a few studies looking at the feasibility to use Campylobacter phages to control these pathogenic bacteria both at the farm-level and on the processed carcass. Once a phage has been characterized and deemed suitable for applications as an antibacterial agent, there will be a number of in-vivo experiments necessary to turn theory into practice.

7.1.1. Use in live birds

Control Campylobacter in the intestine of experimentally colonized birds. Wagenaar and colleagues were one of the first to investigate the application of a single Campylobacter phage type in live broilers as well as test the effect of a two-phage treatment. They postulated that the addition of a second phage might reduce the rate of phage-resistant mutants developing, although the presence of such mutants was not tested for. The authors state that the efficacy of the combination of phages was comparable to their individual effects seen with in-vitro studies, to determine that no antagonistic effect would occur (**Wagenaar et al., 2005**). Loc-Carrillo and colleagues studied two Campylobacter phages (CP8 and CP34) in an in-vivo model, based on in-vitro efficacy studies. Birds pre-colonized with two different wild-type Campylobacter strains resulted in different outcomes after being treated with phage CP8. A significant drop in the population of *C. jejuni* GIIC8 colonizing the ceca, after 1 day of treatment, was seen compared to the relatively unaffected HPC5 population. However, when phage CP34 was used, the treatment produced different results to phage CP8 against the *C. jejuni* HPC5 colonizing the ceca, where the drop in bacterial load was not only lower but also maintained for up to day 5 post treatment. Interestingly, the in-vivo results were contrary to in-vitro results and the ability of phage CP8 in killing *C. jejuni* HPC5 in-vitro was not reproduced in the treated chickens (**Loc Carrillo et al., 2005**), most likely due to the vastly different environments the bacterial population encountered between the chicken gut and as homogeneously grown planktonic cells in a flask. **El-Shibiny et al. (2009)** conducted similar in-vivo studies with a wild-type *C. coli* OR12 strain that was used to colonize the birds and treated with the same phage dosages. Only the highest dose of 109 PFU reduced the Campylobacter counts in the ceca by 1–2 Logs within the first 2 days (**El-Shibiny et al., 2009**). Carvalho and colleagues tested the efficacy of a phage cocktail on chicks colonized by *C. jejuni* or *C. coli*. The phages chosen had different complimentary lytic spectra. Phage treatment delivered through the feed appeared to produce a slightly higher reduction of *C. coli* when compared to administration by oral gavage. To minimize the number of birds culled over the whole study, fecal and cloacal swab samples were used to enumerate the number of Campylobacter excreted by the chicks. Investigating the rate of phage resistance development in Campylobacters passaged through the chick guts, they found 6% of the isolates were resistant to phage despite not being exposed to the phage treatment, in comparison to 13% of isolates that showed phage resistance after being exposed to phage treatment. After passaging the resistant strains back through the chicken gut, they found 86% of the colonies that were previously phage-resistant without exposure to phage had reverted back to being sensitive, whereas only 54% of the colonies that were phage-resistant after being exposed to the phage treatment reverted back to their sensitive phenotype (**Carvalho et al., 2010**).

7.1.2. Use in food products

The use of phages to control the level of Campylobacter contamination on the surface of chicken carcasses has also been investigated by a number of research groups. Two of the studies used chicken skin tainted with known concentrations of susceptible Campylobacter cells (**Goode et al., 2003; Atterbury et al., 2003**), while another used raw and cooked beef products with high and low bacterial loads treated with high and low phage titers (**Bigwood et al., 2008**). In a later study involving polynomial modeling, Bigwood and colleagues calculated that an MOI of 105 would be required to kill at least 25% of a susceptible bacterial population on the surface of food within a 2 h period (**Bigwood et al., 2009**).

Summary

Campylobacter spp. has become one of the most challenging bacteria to eradicate in the past few decades. This bacterium possesses exceptional surviving abilities and can persist in extreme conditions such as the gut and human gastrointestinal system as a result of its ability to withstand an alkaline milieu. In dentistry

Campylobacter spp. is one of the main bacteria associated with chronic apical periodontitis in failed gastrointestinal treatments.

Despite the fact that endodontic infections have a polymicrobial nature, the gastrointestinal environment may favor and support the survival of one species, which is commonly *Campylobacter jejuni* and *Campylobacter coli*. *Campylobacter jejuni* and *Campylobacter coli* is actually seldom present in primary endodontic infections, in cases of postendodontic treatment with apical periodontitis, failed cases are approximately nine times more likely to harbor *Campylobacter jejuni* and *Campylobacter coli* than cases of primary infections. *Campylobacter jejuni* and *Campylobacter coli* which isolated chicken intestine usually carry virulence factors related to adhesions and biofilm formation, which facilitate its colonization of different gastrointestinal sites and enable it to cause severe infections. Moreover, isolates from gastrointestinal infections may carry certain antibiotic resistant determinant that has the ability to be transferred to other pathogenic bacteria in biofilm communities. *Campylobacter jejuni* and *Campylobacter coli* biofilms enable it to resist traditional antibacterial rinsing solutions such as chlorhexidine or sodium hypochlorite and adapt themselves and grow in the presence of calcium hydroxide. *Campylobacter jejuni* and *Campylobacter coli* form biofilm in between gastrointestinal parts without being affected by treatment. The increasing number of antibiotic-resistant *Campylobacter jejuni* and *Campylobacter coli* and biofilm formation, together with the failure of antiseptic rinsing or antibacterial dressing to combat them, require alternative methods to be developed and executed. The use of lytic bacteriophages is one of the most promising techniques that are exploring to fight multidrug resistant *Campylobacter jejuni* and *Campylobacter coli* and their biofilms.

REFERENCES

- Ackermann, H.W. (2001):** Frequency of morphological phage descriptions in the year 2000. Archives of virology, 146(5), 843-857.
- Atterbury, R. J., Connerton, P. L., Dodd, C. E., Rees, C. E., and Connerton, I. F. (2003):** Application of host-specific bacteriophages to the surface of chicken skin leads to a reduction in recovery of *Campylobacter jejuni*. Appl. Environ. Microbiol. 69, 6302–6306. doi: 10.1128/aem.69.10.6302-6306.2003
- Bhunia, A.K. (2018):** *Campylobacter* and *Arcobacter*, in Foodborne Microbial Pathogens. Springer, 289-299.
- Bigwood, T., Hudson, J.A., Billington, C., (2009):** Influence of host and bacteriophage concentrations on the inactivation of food-borne pathogenic bacteria by two phages. FEMS Microbiol. Lett. 291, 59–64.
- Bigwood, T., Hudson, J.A., Billington, C., Carey-Smith, G.V., Heinemann, J.A., (2008):** Phage inactivation of foodborne pathogens on cooked and raw meat. Food Microbiol. 25, 400–406.
- Carrillo, C.L.; Atterbury, R.; El-Shibiny, A.; Connerton, P.; Dillon, E.; Scott, A. and Connerton, I. (2005):** Bacteriophage Therapy to Reduce *Campylobacter jejuni* Colonization of Broiler Chickens. Appl. Environ. Microbiol. 2005, 71, 6554–6563.
- Carvalho, C.M.; Gannon, B.W.; Halfhide, D.E.; Santos, S.B.; Hayes, C.M.; Roe, J.M. and Azeredo, J. (2010):** The in vivo efficacy of two administration routes of a phage cocktail to reduce numbers of *Campylobacter coli* and *Campylobacter jejuni* in chickens. BMC Microbiol. 2010, 10, 232.
- Carvalho, C.M.; Kropinski, A.M.; Lingohr, E.J.; Santos, S.B.; King, J. and Azeredo, J. (2012):** The Genome and Proteome of a *Campylobacter coli* Bacteriophage vb_Ccom-Ibb_35 Reveal Unusual Features. Virol. J. 2012,9,35.
- Chaître, P.; Haenni, M.; Meunier, D.; Botrel, M.; Calavas, D. and Madec, JY. (2010):** Prevalence and antimicrobial resistance of *Campylobacter jejuni* and *Campylobacter coli* isolated from cattle between 2002 and 2006 in France. J Food Prot.2010; 73:825–31. <https://doi.org/10.4315/0362-028x-73.5.825> PMID: 20501032
- Connerton, P. L.; Loc Carrillo, C. M.; Swift, C.; Dillon, E.; Scott, A.; Rees, C. E.; et al., (2004):** Longitudinal study of *Campylobacter jejuni* bacteriophages and their hosts from broiler chickens. Appl. Environ. Microbiol. 70, 3877–3883. doi: 10.1128/aem.70.7.3877-3883.2004
- Connerton, P. L.; Timms, A. R. and Connerton, I. F. (2011):** *Campylobacter* bacteriophages and bacteriophage therapy. J. Appl. Microbiol. 111, 255–265. doi: 10.1111/j.1365-2672.2011.05012.x
- Dadi, L and Asrat, D. (2008):** Prevalence and antimicrobial susceptibility of thermotolerant *Campylobacter* strains in retail raw meat products in Ethiopia. Ethiop J Health Dev.2008; 22:195–6.
- Dasti, J.I.; Tareen, A.M.; Lugert, R.; Zautner, A.E. and Groß, U. (2010):** *Campylobacter jejuni*: a brief overview on pathogenicity-associated factors and disease-mediating mechanisms. Int J Med Microbiol, 300(4): 205-211.
- Denis M, Soumet C, Rivoal K, Ermel G, Blivet D, Salvat G, et al. (1999):** Development of m-PCR for simultaneous identification of *C. jejuni* and *C. coli*. Lett Appl Microbiol.1999; 29:406–10.

- El-Shibiny, A.; Scott, A.; Timms, A.; Metawea, Y.; Connerton, P. and Connerton, I. (2009):** Application of a group II *Campylobacter* bacteriophage to reduce strains of *Campylobacter jejuni* and *Campylobacter coli* colonizing broiler chickens. *J. Food Prot.* 2009, 72, 733–740.
- Goode, D., Allen, V. M., and Barrow, P. A. (2003):** Reduction of experimental Salmonella and *Campylobacter* contamination of chicken skin by application of lytic bacteriophages. *Appl. Environ. Microbiol.* 69, 5032–5036. doi: 10.1128/aem.69.8.5032-5036.2003
- Gurtler, M.; Alter, T.; Kasimir, S. and Fehlhabe, K. (2005):** The importance of *Campylobacter coli* in human campylobacteriosis: Prevalence and genetic characterization. *Epidemiology and Infection* 133: 1081-1087.
- Hagos Y, Gugsu G, Awol N, Ahmed M, Tsegaye Y, Abebe N, et al. (2021): Isolation, identification, and antimicrobial susceptibility pattern of *Campylobacter jejuni* and *Campylobacter coli* from cattle, goat, and chicken meats in Mekelle, Ethiopia. *PLoS ONE* 16(2): e0246755
- Halablal, M.A., Mohammed, K.A.S. and Miles, R.J. (2008):** Growth and survival of *Campylobacter* pathogens in the presence of different metabolic inhibitors. *J. Medical Sci.*, 8 (3): 262-268.
- Hammerl, J.A.; Jäckel, C.; Reetz, J.; Beck, S.; Alter, T.; Lurz, R.; Barretto, C.; Brüssow, H. and Hertwig, S. (2011):** *Campylobacter jejuni* Group III Phage CP81 Contains Many T4-Like Genes without Belonging to the T4-Type Phage Group: Implications for the Evolution of T4 Phages. *J. Virol.* 2011, 85, 8597–8605.
- Hansen, V.M.; Rosenquist, H.; Baggesen, D.L.; Brown, S. and Christensen, B.B. (2007):** Characterization of *Campylobacter* Phages Including Analysis of Host Range by Selected *Campylobacter* Penner Serotypes. *BMC Microbiol.* 2007, 7, 90.
- Holst Sorensen, M.C., van Alphen, L.B., Harboe, A., Li, J., Christensen, B.B., Szymanski, C.M., Brondsted, L., (2011):** Bacteriophage F336 recognizes the capsular phosphoramidate modification of *Campylobacter jejuni* NCTC11168. *J. Bacteriol.* 193, 6742–6749.
- Humphrey, T.; O'Brien, S. and Madsen, M. (2007):** *Campylobacters* as zoonotic pathogens: A food production perspective. *Int. J. Food Microbiol.* 2007, 117, 237–257.
- Iovine, N.M. (2013):** Resistance mechanisms in *Campylobacter jejuni*. *Virulence*, 4(3): 230-240
- ISO, International Organisation for Standardisation (2006):** Microbiology of food and animal feeding stuffs – Horizontal method for the detection and enumeration of *Campylobacter* spp. Part 1: Detection method. ISO 10272-1:2006: 1-16.
- Janez, N.; Loc Carrillo, C. (2013): Use of phages to control *Campylobacter* spp. *J. Microbiol. Methods* 2013, 95, 68–75. [CrossRef] [PubMed]
- Jeon, B., Wang, Y., Hao, H., Barton, Y.W. and Zhang, Q. (2011):** Contribution of CmeG to antibiotic and oxidative stress resistance in *Campylobacter jejuni*. *J. Antimicrob. Chemother.*, 66 (1):79-85
- Kaakoush, N. O., Castaño-Rodríguez, N., Mitchell, H. M., and Man, S. M. (2015):** Global epidemiology of *Campylobacter* infection. *Clin. Microbiol. Rev.* 28, 687–720. doi: 10.1128/cmr.00006-15
- Kropinski, A.M.; Arutyunov, D.; Foss, M.; Cunningham, A.; Ding, W.; Singh, A.; Pavlov, A.R.; Henry, M.; Evoy, S.; Kelly, J.; et al. (2011):** Genome and Proteome of *Campylobacter jejuni* Bacteriophage NCTC 12673. *Appl. Environ. Microbiol.* 2011, 77, 8265–8271. [CrossRef]
- Loc Carrillo, C.; Atterbury, R.J.; Dillon, E.; Scott, A.; Connerton, I.F.; Connerton, P.L. (2005): Bacteriophage Therapy To Reduce *Campylobacter jejuni* Colonization of Broiler Chickens. *Appl. Environ. Microbiol.* 2005, 71, 6554–6563. [CrossRef]
- Mäesaar, M., Praakle, K., Meremäe, K., Kramarenko, T., Sögel, J., Viltrop, A., Muutra, K., Kovalenko, K., Matt, D., Hörman, A., Hänninen, M. and Roasto, M. (2014):** Prevalence and counts of *Campylobacter* spp. in poultry meat at retail level in Estonia. *Food Control*, 44:72-77.
- Nachamkin, I. (2007):** *Campylobacter jejuni*. Ch 11 In: Doyle MP, Beuchat LR (eds) *Food microbiology: Fundamentals and frontiers*. 3rd ed, ASM Press, Washington D.C., p. 237-248.
- Newell, D. G., and C. Fearnley. (2003):** Sources of *Campylobacter* colonization in broiler chickens. *Appl. Environ. Microbiol.* 69:4343– 4351.
- Nonga HE, Sells P, Karimuribo ED. (2010):** Occurrences of thermophilic *Campylobacter* in cattle slaughtered at Morogoro municipal abattoir, Tanzania. *Tropi Animal Heal Productio.*2010; 42:73–8. <https://doi.org/10.1007/s11250-009-9387-7> PMID: 19551483
- Oberhelman RA, Taylor DN. (2000):** *Campylobacter* infections in developing countries. In: *Campylobacter*, 2nd ed.; Nachamkin I., Blaser M.J., Eds.; Washington DC: American Society of Microbiology (SAM) Press; 2000, pp. 139–53. [https://doi.org/10.1016/s0360-3016\(00\)00774-4](https://doi.org/10.1016/s0360-3016(00)00774-4) PMID: 11121652
- Owens, J., Barton, M.D., Heuzenroeder, M.W., (2012):** The isolation and characterization of *Campylobacter jejuni* bacteriophages from free range and indoor poultry. *Vet. Microbiol.* 162 (1), 144–150.

- Page, W.J., Huyer, G., Huyer, M. and Worobec, E.A. (1989):** Characterization of the porins of *Campylobacter jejuni* and *Campylobacter coli* and implications for antibiotic susceptibility. *Antimicrob. Agents Chemother.*, 33(3):297-303.
- Park P. (2002):** The physiology of *Campylobacter* species and its relevance to their role as foodborne pathogens. *International Journal of Food Microbiology*. 74: 177-188.
- Sails, A.D.; Wareing, D.R.; Bolton, F.J.; Fox, A.J.; Curry, A. (1998):** Characterisation of 16 *Campylobacter jejuni* and *C. coli* Typing Bacteriophages. *J. Med. Microbiol.* 1998, 47, 123–128. [CrossRef]
- Salihu MD, Junaidu AU, Oboegbulem SI, Egwu GO. (2009):** Prevalence and biotypes of *Campylobacter* spp. isolated from sheep in Sokoto state, Nigeria. *Int J Anim VetAd.*2009; 1:6–9.
- Sambrook J, Russel WD. (2007):** Molecular cloning a laboratory manual 3rd ed. Cold Spring Harbour, NY: Cold Spring Harbour Laboratory Press; 2007.
- Sambrook, J.; Russell, D. (2001):** Molecular Cloning: A Laboratory Manual; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, USA, 2001.
- Scott, A.E., Timms, A.R., Connerton, P.L., Loc Carrillo, C., Adzfa Radzum, K., Connerton, I.F., (2007):** Genome dynamics of *Campylobacter jejuni* in response to bacteriophage predation. *PLoS Pathog.* 3, e119.
- Song, Y.C., Jin, S., Louie, H., Ng, D., Lau, R., Zhang, Y., Weerasekera, R., Al Rashid, S., Ward, L.A., Der, S.D. and Chan, V.L. (2004):** FlaC, a protein of *Campylobacter jejuni* TGH9011 (ATCC43431) secreted through the flagellar apparatus, binds epithelial cells and influences cell invasion. *Mol. Microbiol.*, 53 (2): 541—553.
- Taremi M, Soltan-Dallal MM, Gachkar L, MoezArdalan S, Zolfagharian K, Zali MR. (2006):** Prevalence and antimicrobial resistance of *Campylobacter* isolated from retail raw chicken and beef meat, Tehran, Iran. *Int J Food Microbiol.* 2006; 108:401–3. <https://doi.org/10.1016/j.ijfoodmicro.2005.12.010P> MID: 16481059
- Thépault A, Poezevara T, Quesne S, Rose V, Chemaly M, Rivoal K. (2018):** Prevalence of Thermophilic *Campylobacter* in Cattle Production at Slaughterhouse Level in France and Link Between *C. jejuni* Bovine Strains and Campylobacteriosis. *Front Microbiol.* 2018 Mar 19;9:471. doi: 10.3389/fmicb.2018.00471. PMID: 29615999; PMCID: PMC5867340.
- Timms, A.R.; Cambray-Young, J.; Scott, A.E.; Petty, N.K.; Connerton, P.L.; Clarke, L.; Seeger, K.; Quail, M.; Cummings, N.; Maskell, D.J.; et al., (2010):** Evidence for a Lineage of Virulent Bacteriophages That Target *Campylobacter*. *BMC Genom.* 2010, 11, 214. [CrossRef] [PubMed]
- Torralbo, A., Borge, C., Allepuz, A., García-Bocanegra, I., Sheppard, S.K., Perea, A. and Carbonero, A. (2014):** Prevalence and risk factors of *Campylobacter* infection in broiler flocks from southern/ Spain. *Prev. Vet. Med.*, 114(2):106-113.
- Van Vliet, A. and Ketley, J. (2001):** Pathogenesis of enteric *Campylobacter* infection. *J Appl Microbiol*, 90(S6): 45S-56S.
- Vanderlinde, PB.; Shay, B. and Murray, J. (1998):** Microbiological quality of Australian beef carcass meat and frozen bulk packed beef. *J Food Prot.*1998; 61:437–43. <https://doi.org/10.4315/0362-028x-61.4.437> PMID: 9709207
- Wagenaar, J. A., Van Bergen, M. A., Mueller, M. A., Wassenaar, T. M., and Carlton, R. M. (2005):** Phage therapy reduces *Campylobacter jejuni* colonization in broilers. *Vet. Microbiol.* 109, 275–283. doi: 10.1016/j.vetmic.2005.06.002.